通心络胶囊联合双抗血小板方案对PCI术后阿司匹林抵抗患者预后的影响

doi:10.3969/j.issn.1006-6233.2018.07.007

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1340 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effect of Tongxinluo capsule combined with dual antiplatelet regimen on the prognosis of patients with aspirin resistance (AR) after percutaneous coronary intervention (PCI). Methods: 100 patients with coronary heart disease (CHD) who had AR after undergoing PCI in the hospital from February 2012 to April 2016 were selected as the subjects. They were randomly divided into the control group and the observation group by the random number table method, 50 cases in each group. The control group was treated with dual antiplatelet regimen, and on the basis, the observation group was treated with Tongxinluo capsule. The degree of platelet aggregation, serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were measured at different time. Changes of cardiac function in patients were determined by echocardiography, and the relief of symptoms of angina pectoris was observed. The two groups were followed up for 1 year, and the incidence of adverse cardiovascular events was statistically analyzed. Results: After 4 weeks of treatment, the platelet aggregation rates of the two groups decreased to varying degrees (P < 0.05), and the platelet aggregation rates induced by AA and ADP in the observation group were lower than those in the control group (P < 0.05). Before treatment, there was no significant difference between the two group in serum lipids or cardiac function indexes (P > 0.05). After 6 months of treatment, the TC, TG, LDL and LVESD in the two groups were decreased, while HDL and LVEF were increased (P < 0.05). The TC, TG, LDL and LVESD in the observation group were lower than those in the control group while HDL and LVEF were higher than those in the control group (P < 0.05). The scores of angina pectoris in the two groups were increased after 6 and 12 months of treatment, and the scores of the observation group were higher than those of the control group (P < 0.05). The incidence of adverse events in the observation group during 1-year follow-up was slightly lower than that in the control group, but there was a significant difference only in the readmission rate (P < 0.05). Conclusion: Tongxinluo capsule combined with dual antiplatelet regimen can improve the blood lipid levels and cardiac function, relieve angina pectoris symptoms, reduce the incidence of cardiovascular adverse events, and improve the prognosis of patients with AR after PCI.

Key words： Percutaneous coronary intervention Aspirin resistance Tongxinluo Antiplatelet therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.07.007 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I7/1081

[1] Guan Q,Liu M,Liu R,et al.Tongxinluo induces nNOS expression through ERK activation:possible contribution to the effects of tongxinluo to attenuate vasoconstriction[J].Journal of Cardiovascular Pharmacology,2015,66(1):9~15.
[2] 李靖,宋书江,许金鹏,等.质子泵抑制剂对经皮冠状动脉介入术后双重抗血小板治疗的影响[J].实用医学杂志,2013,29(13):2195~2197.
[3] 王学忠,龚晓璇,朱甜甜,等.联合氯吡格雷和阿司匹林抗血小板治疗对非体外循环冠状动脉旁路移植术后患者阿司匹林抵抗的影响[J].中国医学科学院学报,2013,35(5):495~502.
[4] 陈斗仁.质子泵抑制剂对PCI术后氯吡格雷抗血小板作用的影响[J].山东医药,2013,53(10):66~68.
[5] 李妙男,王洪巨,汤阳,等.血浆细胞色素P4502C19基因多态性与皖北汉族急性冠脉综合征患者氯吡格雷抵抗及冠脉介入术后近期预后的关系[J].临床心血管病杂志,2016,21(3):272~276.
[6] 郑若龙,陈新军,钱惠东,等.急性心肌梗死患者双联抗血小板治疗加用质子泵抑制剂对预后的影响[J].实用医学杂志,2013,29(9):1465~1467.
[7] Li N,Yang Y J,Cui H H,et al.Tongxinluo decreases apoptosis of mesenchymal stem cells concentration-dependently under hypoxia and serum deprivation conditions through the AMPK/eNOS pathway.[J].Journal of Cardiovascular Pharmacology,2014,63(3):265~273.
[8] 马元,丁亚辉,屈百鸣,等.PCI术后早期抗血小板药物反应性与西雅图心绞痛量表评分的相关性研究[J].中国现代应用药学,2017,34(4):587~590.
[9] Liu Y,Tang G H,Sun Y H,et al.The protective role of Tongxinluo on blood-brain barrier after ischemia-reperfusion brain injury.[J].Journal of Ethnopharmacology,2013,148(2):632~639.
[10] Li X,Zhang J,Zhao W,et al.Effect of Tongxinluo on nerve regeneration in mice with diabetic peripheral neuropathy.[J].Cellular and molecular biology(Noisy-le-Grand,France),2015,61(5):103~107.
[11] 陈国友,钱玉凤,方存明.通心络胶囊对冠心病患者PCI术后血清亲环素A和基质金属蛋白酶9的影响[J].中国药房,2017,28(24):3365~3367.
[12] 李红昆,陆永光,严华,等.通心络对急性心肌梗死患者PCI术后血清EMPs及MMP-9的影响[J].重庆医学,2016,45(3):354~355.
[13] 田昭涛,李慧丽,李坤.通心络胶囊干预急性心肌梗死经皮冠状动脉介入治疗术后30例[J].中国实验方剂学杂志,2014,20(2):196~200.
[14] 陈章强,洪浪,王洪,等.通心络对AMI延迟介入治疗术后血小板活化因子、血管内皮功能、TIMI血流分级的影响[J].中国中西医结合杂志,2016,36(4):415~420.
[15] Zheng C Y,Song L L,Wen J K,et al.Tongxinluo(TXL),a Traditional Chinese medicinal compound,improves endothelial function after chronic hypoxia both in vivo and in vitro[J].Journal of Cardiovascular Pharmacology,2015,65(6):579~586.
[16] 陆宏伟,张健,陈欣,等.通心络胶囊联合西药预防经皮冠状动脉介入术后冠状动脉再狭窄90例临床观察[J].中医杂志,2014,55(24):2117~2120.
[17] Wang J,Xiong X,Liu W.Chinese patent medicine tongxinluo capsule for hypertension:a systematic review of randomised controlled trials[J].Journal of the American College of Cardiology,2014,2014(1):187979.
[18] 王志永,齐向前,张健.冠状动脉支架术后阿司匹林和小剂量氯吡格雷双联抗血小板治疗长期随诊[J].中华老年医学杂志,2013,32(4):448~451.
[19] 邓丽立,程效雄.通心络胶囊联合阿托伐他汀钙片对冠心病患者血脂及炎症因子影响药理分析[J].辽宁中医药大学学报,2016,18(9):190~192.
[20] Li B,Li Y,Liu K,et al.High glucose decreases claudins-5 and-11 in cardiac microvascular endothelial cells:Antagonistic effects of tongxinluo[J].Endocrine Research,2016,42(1):15~21.